Brentuximab vedotin
Also known as: Adcetris, Brentuximab vedotin, cAC10-vcMMAE, SGN-35
Source Brentuximab vedotin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Brentuximab vedotin is a chimeric IgG1 antibody‑drug conjugate that binds CD30 on malignant cells and delivers the cytotoxic payload monomethyl auristatin E. It is approved for relapsed or refractory CD30‑positive Hodgkin’s lymphoma and is used in combination regimens for newly diagnosed advanced Hodgkin’s disease and CD30‑positive peripheral T‑cell lymphomas.
Mechanism of Action
The antibody portion of brentuximab vedotin recognizes the CD30 antigen expressed on certain lymphoma cells. After binding, the complex is internalized and the protease‑cleavable linker releases monomethyl auristatin E inside the cell. MMAE disrupts microtubule polymerisation, leading to cell‑cycle arrest and apoptosis of the CD30‑positive tumor cell.
What the Research Shows
In the ECHELON‑1 phase 3 trial (664 patients), brentuximab vedotin plus doxorubicin, vinblastine and dacarbazine (A+AVD) improved 2‑year modified progression‑free survival to 82.1% versus 77.2% with ABVD (hazard ratio 0.77) but increased neutropenia (58% vs 45%) and peripheral neuropathy (67% vs 43%). A later phase 3 study (994 patients) compared brentuximab vedotin‑AVD with nivolumab‑AVD; nivolumab‑AVD yielded higher 2‑year progression‑free survival (92% vs 83%) and fewer treatment discontinuations. The ECHELON‑2 trial in CD30‑positive peripheral T‑cell lymphoma showed that brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone (A+CHP) achieved 5‑year progression‑free survival of 51.4% versus 43.0% with CHOP (hazard ratio 0.70) and improved 5‑year overall survival (70.1% vs 61.0%). Neuropathy was common but resolved or improved in the majority of patients.
Reported Benefits
Clinical trials demonstrate that adding brentuximab vedotin to standard chemotherapy modestly improves progression‑free survival in advanced‑stage Hodgkin’s lymphoma and provides a clear survival advantage in CD30‑positive peripheral T‑cell lymphoma. The drug also enables a chemo‑free approach (nivolumab‑AVD) that achieved superior progression‑free survival with fewer discontinuations. Neuropathy, when it occurs, often improves over time.
Limitations of the Evidence
The absolute benefit in Hodgkin’s disease is modest (≈5% improvement in 2‑year PFS) and comes with higher rates of neutropenia and peripheral neuropathy. Long‑term safety beyond several years remains limited. Head‑to‑head comparisons with other novel agents are lacking, and data in pediatric populations are sparse. The superiority of nivolumab‑AVD over brentuximab‑AVD reflects a different regimen rather than a direct endorsement of brentuximab alone.
Safety Considerations
The most frequent adverse events are neutropenia (58% with A+AVD) and peripheral neuropathy (67% with A+AVD, 43% with ABVD). Grade 3 or higher pulmonary toxicity is rare with brentuximab regimens (<1%). Neuropathy resolves or improves in about two‑thirds of affected patients. When combined with nivolumab, immune‑related events are infrequent, but brentuximab‑containing arms have higher treatment discontinuation rates due to toxicity. Careful monitoring of blood counts and neurologic function is advised.
How It Is Administered
Brentuximab vedotin is administered intravenously, typically as part of multi‑agent chemotherapy protocols such as A+AVD for Hodgkin’s lymphoma or A+CHP for peripheral T‑cell lymphoma. It is given on a scheduled cycle (often every 2–3 weeks) in a clinical setting; formulation details and exact dosing schedules are defined in trial protocols and product labeling.
Routes of Administration
Goals & Uses
- Classical Hodgkin lymphoma (relapsed/refractory)OncologyHigh
- Primary cutaneous ALCL or CD30-expressing mycosis fungoidesOncologyHigh
- Systemic ALCLOncologyHigh
- Systemic anaplastic large cell lymphoma (relapsed/refractory)OncologyHigh
- Previously untreated Stage III/IV cHL (with AVD)OncologyHigh
- Post-ASCT consolidation in cHL at high risk of relapseOncologyHigh
- Previously untreated CD30+ peripheral T-cell lymphomaOncologyHigh
- Hodgkin lymphomaOncologyHigh
Contraindications
- Known severe hypersensitivity to brentuximab vedotinHypersensitivityHigh
- Concurrent bleomycin useDrug CombinationHigh
- Known hypersensitivity to brentuximab vedotin or any componentAllergyHigh
- Progressive multifocal leukoencephalopathy (PML) riskNeurologicalHigh
Adverse Effects
- Peripheral neuropathyNeurologicalCommon
- Infusion‑related reactionsGeneralUncommon
- Progressive multifocal leukoencephalopathy (PML)NeurologicalRare
- Nausea and vomitingGastrointestinalCommon
- NeutropeniaHematologicCommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
- Peripheral sensory neuropathyNeurologicalCommon
- FeverSystemicCommonElevated body temperature
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- BleomycinHigh
- Strong CYP3A4 inducers (e.g., rifampin)Moderate
- Strong CYP3A4 inhibitors (e.g., ketoconazole)Moderate
- P-glycoprotein inhibitorsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairment (moderate to severe)Organ ImpairmentRelative
- Pediatric patientsAgeRelative
- Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Hodgkin lymphoma, Systemic anaplastic large‑cell lymphomaEMA approval 2012
- United StatesApprovedApproved: Hodgkin lymphoma, Systemic anaplastic large‑cell lymphomaFDA approval 2011
- United KingdomApprovedApproved: Hodgkin lymphoma, Systemic anaplastic large‑cell lymphomaMHRA approval
Approved by FDA (2011) and EMA; marketed under the brand Adcetris; contains monomethyl auristatin E linked via a protease‑cleavable valine‑citrulline linker.
Evidence & Sources
- Journal ArticleModerateConnors JM, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleModerateHerrera AF, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateHorwitz S, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateBartlett NL, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateThomas A, Teicher BA, Hassan R2016-01-01T00:00:00.000000Z
- Journal ArticleModerateHorwitz S, et al.2019-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of cancer is brentuximab vedotin approved to treat?
It is approved for relapsed or refractory CD30‑positive Hodgkin’s lymphoma and has been studied in newly diagnosed advanced Hodgkin’s disease and CD30‑positive peripheral T‑cell lymphomas as part of combination regimens.
How does brentuximab vedotin differ from traditional chemotherapy?
It targets the CD30 antigen on tumor cells, delivering a potent microtubule inhibitor directly into those cells, whereas conventional chemotherapy affects both cancerous and many normal dividing cells.
What are the most common side effects?
Neutropenia and peripheral neuropathy are the most frequently reported; neuropathy often improves over time, and febrile neutropenia can be mitigated with growth‑factor support.
Is brentuximab vedotin used alone or with other drugs?
In approved and trial settings it is combined with chemotherapy agents (e.g., AVD, CHP) or with immunotherapy (nivolumab) to enhance efficacy; it is not typically given as monotherapy for frontline disease.
What is Brentuximab vedotin?
Brentuximab vedotin is a chimeric IgG1 antibody‑drug conjugate that binds CD30 on malignant cells and delivers the cytotoxic payload monomethyl auristatin E. It is approved for relapsed or refractory CD30‑positive Hodgkin’s lymphoma and is used in combination regimens for newly diagnosed advanced Hodgkin’s disease and CD30‑positive peripheral T‑cell lymphomas.
What is Brentuximab vedotin used for?
Brentuximab vedotin is educationally associated with: Classical Hodgkin lymphoma (relapsed/refractory), Primary cutaneous ALCL or CD30-expressing mycosis fungoides, Systemic ALCL, Systemic anaplastic large cell lymphoma (relapsed/refractory), Previously untreated Stage III/IV cHL (with AVD), Post-ASCT consolidation in cHL at high risk of relapse, Previously untreated CD30+ peripheral T-cell lymphoma, Hodgkin lymphoma. Educational only — not medical advice.
How is Brentuximab vedotin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Brentuximab vedotin?
Reported adverse effects include: Peripheral neuropathy, Infusion‑related reactions, Progressive multifocal leukoencephalopathy (PML), Nausea and vomiting, Neutropenia, Fatigue, Peripheral sensory neuropathy, Fever, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Brentuximab vedotin?
Recorded contraindications: Known severe hypersensitivity to brentuximab vedotin, Concurrent bleomycin use, Known hypersensitivity to brentuximab vedotin or any component, Progressive multifocal leukoencephalopathy (PML) risk. Consult a qualified clinician before use.